Parke-Davis May Not Get GW Products
It appears increasingly unlikely that Parke-Davis (India) will get useof the five drug products which Glaxo Wellcome has transferred to the company's US partner, Warner-Lambert.
W-L companies worldwide will have first right of refusal on over-the-counter medicines Actifed, Sudafed and Nix, as well as the antibiotics Neosporin and Polysporin, although it is thought by Indian drug industry sources that the US group's wholly-owned Indian company, WarnerLambert India Pvt Ltd, will take over the brands rather than Parke-Davis, in which W-L has a 40% stake.
Furthermore, there is some doubt as to whether W-L in India will have to pay any fees for the products, or if the worldwide deal covers the costs. The cold preparations Actifed and Neosporin are large contributors to sales at Burroughs Wellcome India compared with Sudafed, while Polysporin and the anti-lice treatment Nix have yet to be launched in India.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze